ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) will release earnings for its first quarter before the opening bell on Friday, May 15.

Analysts expect the San Diego, California-based company to report quarterly loss of 54 cents per share, versus a loss of 35 cents per share in the year-ago period. The consensus estimate for ARS Pharmaceuticals' quarterly revenue is $22.12 million (it reported $7.97 million last year), according to Benzinga Pro.

On May 13, ARS Pharmaceuticals named Donn Casale as president.

Shares of ARS Pharmaceuticals fell 0.9% to close at $7.94 on Thursday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.

  • Roth Capital analyst Jason Wittes initiated coverage on the stock with a Buy rating and a price target of $40 on Sept. 4, 2025. This analyst has an accuracy rate of 54%.
  • Scotiabank analyst Louise Chen initiated coverage on the stock with a Sector Outperform rating and a price target of $30 on March 7, 2025. This analyst has an accuracy rate of 60%.
  • Raymond James analyst Ryan Deschner maintained a Strong Buy rating and raised the price target from $26 to $28 on Jan. 14, 2025. This analyst has an accuracy rate of 80%.

Considering buying SPRY stock? Here’s what analysts think:

Photo via Shutterstock